Skip to content
Screener

PTC Therapeutics PTCT Debt-to-equity

Discontinued — last reported Q4 '21

Debt-to-equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.1×0.0×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
0.7×+0.6×
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
0.1×0.0×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.9×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
0×0.0×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.2×

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×—
P/S7×+4.7×

Profitability

See full
Gross margin96%—
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%—
Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

total debt/total stockholders equity=372.3×

Based on the most recent quarter.

The source filing: PTC Therapeutics’s 10-K, filed February 21, 2023. Open the filing →

Filed
Feb 21, 2023
Fiscal year
FY2022
Accession
0001070081-23-000011

FAQ

What is PTC Therapeutics's debt-to-equity?
PTC Therapeutics (PTCT) reported debt-to-equity of 372.3× in Q4 2021.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about PTC Therapeutics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude